Cover Image

Department of Justice Announces Membership Changes in Subcutaneous Drug Development & Delivery Consortium, Inc.

Estimated reading time: 3–5 minutes

On May 23, 2025, the Subcutaneous Drug Development & Delivery Consortium, Inc. filed official notifications about changes in its group membership. This was done under section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 et seq.

The notification was sent to both the Attorney General and the Federal Trade Commission. The purpose was to extend protections under the Act. These protections limit antitrust plaintiffs to actual damages in certain cases.

Four new parties have joined the consortium. They are Matchstick LLC from Boonton, New Jersey; Gilead Sciences, Inc. from Forest City, California; SHL Medical AG from Zug, Switzerland; and Regeneron Pharmaceuticals, Inc. from Tarrytown, New York.

No other changes were made to the membership or to the planned activities of the group research project. Membership in the research project remains open. The Consortium plans to file more notifications if there are membership changes in the future.

The original notification for the Consortium was filed on October 26, 2020. The Department of Justice published a notice about this in the Federal Register on December 3, 2020 (85 FR 78148).

The most recent membership update before this one was filed on October 4, 2024. A notice of that filing was published in the Federal Register on December 20, 2024 (89 FR 104209).

This announcement was signed by Suzanne Morris, Deputy Director of Civil Enforcement Operations, Antitrust Division.

[Federal Register, Volume 90, Number 113, Friday, June 13, 2025, Page 25081]


Legal Disclaimer

This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.